Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurogene Inc.NGNE · Entity 5160 | Chief Scientific Officer | March 13, 2026 | March 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurogene Inc.
Report date March 13, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,497 |
Last balance in matching sequence
After 2026-03-13 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-03-13 · Sale · Disposed 3,991 · Balance 33,303 F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.94 to $20.93, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. Row 2 · 2026-03-13 · Sale · Disposed 2,658 · Balance 30,645 F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025. F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.97 to $21.96, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. Row 3 · 2026-03-13 · Sale · Disposed 148 · Balance 30,497 F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025. F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.97 to $22.16, inclsuive. The reporting person undertakes to provide Neurogene Inc. the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.94 to $20.93, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.97 to $21.96, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.97 to $22.16, inclsuive. The reporting person undertakes to provide Neurogene Inc. the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2026 Filed Mar 17, 2026 22:01 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 148 | $22.08 | $3,267.84 |
DisclosureSEC source: 0001994301-26-000004 · wk-form4_1773784904.xml · nonDerivative · entry 3 Cobb Stuart · CIK 0001994301 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,497 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.97 to $22.16, inclsuive. The reporting person undertakes to provide Neurogene Inc. the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 22:01 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 2,658 | $21.34 | $56,721.72 |
DisclosureSEC source: 0001994301-26-000004 · wk-form4_1773784904.xml · nonDerivative · entry 2 Cobb Stuart · CIK 0001994301 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,645 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.97 to $21.96, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 22:01 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 3,991 | $20.41 | $81,456.31 |
DisclosureSEC source: 0001994301-26-000004 · wk-form4_1773784904.xml · nonDerivative · entry 1 Cobb Stuart · CIK 0001994301 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,303 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.94 to $20.93, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:49 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantCommon Stock | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001994301-26-000002 · wk-form4_1771976976.xml · nonDerivative · entry 1 Cobb Stuart · CIK 0001994301 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,294 F1 · shares: Consist of 16,500 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. F2 · balance_after: Consist of (a) 13,594 restricted stock units remaining from a grant of 20,391 restricted stock units granted on March 13, 2024, which vests annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 7,200 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:43 UTC | Neurogene Inc. NGNE · Entity 5160 | SaleCommon Stock | 6,797 | $15.15 | $103,003.10 |
DisclosureSEC source: 0001404644-25-000046 · wk-form4_1747341779.xml · nonDerivative · entry 1 Cobb Stuart · CIK 0001994301 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,794 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.78 to $15.75. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 26, 2025 Filed Mar 29, 2025 01:30 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantEmployee Stock Option (Right to buy) · Derivative | 42,900 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0001404644-25-000025 · wk-form4_1743211830.xml · derivative · entry 2 Cobb Stuart · CIK 0001994301 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,900 Underlying: Common Stock · 42,900 shares Expires 2035-03-26 F2 · derivative.exercise_date: This option represents the right to purchase 42,900 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal month installments through the fourth anniversary of the grant date. Read SEC document |
| March 26, 2025 Filed Mar 29, 2025 01:30 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantCommon Stock | 7,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001404644-25-000025 · wk-form4_1743211830.xml · nonDerivative · entry 1 Cobb Stuart · CIK 0001994301 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,591 F1 · shares: Consists of 7,200 restricted stock units, which will vest in three equal annual installments beginning with the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 00:51 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 34,450 | $0.00 Strike: $36.06 | $0.00 |
DisclosureSEC source: 0001404644-24-000006 · wk-form4_1710463892.xml · derivative · entry 2 Cobb Stuart · CIK 0001994301 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,450 Underlying: Common Stock · 34,450 shares Expires 2034-03-13 F1 · derivative.exercise_date: The option vests as to 1/4 of the total number of shares on March 13, 2025, and then 1/48 of the total number of shares will vest monthly thereafter, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 00:51 UTC | Neurogene Inc. NGNE · Entity 5160 | GrantCommon Stock | 20,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001404644-24-000006 · wk-form4_1710463892.xml · nonDerivative · entry 1 Cobb Stuart · CIK 0001994301 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,391 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.